Capping more than two years of stock-gyrating drama, Pfizer said it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

Outside the US, Enbrel is marketed by Pfizer – but it also faces competition in Europe from another near-copy from Samsung Bioepis. The US is lagging behind Europe in the field of biosimilars ...

Pfizer PFE will report its first-quarter earnings on April 29, before market open. The Zacks Consensus Estimate for sales and ...

Enbrel, which Amgen markets inside the US under an agreement with Pfizer, is still Amgen’s biggest selling drug. In Q2 alone it generated sales of more than $1.3 billion almost entirely from the ...

Amgen sued the board in March 2024, after it declared Enbrel unaffordable for Colorado patients. The drugmaker argued not only that the board’s decision was wrong, but that the law setting up ...

Counsel for Amgen in the related case argue the company is immune from suit as the exclusive U.S. pharmaceutical patent holder of blockbuster rheumatoid arthritis treatment Enbrel. A new lawsuit ...

Enbrel revenues declined 16% to $169 million. New product Oxbryta generated sales of $17 million in the third quarter of 2024, down 80% year over year. In September, Pfizer announced that it is ...

Counsel for Amgen in the related case argue the company is immune from suit as the exclusive U.S. pharmaceutical patent holder of blockbuster rheumatoid arthritis treatment Enbrel. A new lawsuit ...

The health sector faces upheavals as Sandoz files an antitrust lawsuit against Amgen over arthritis drug market ...